NCT00130858已完成2 期
a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4
Cooperative Weichteilsarkom Study Group71 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2005年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 90
- 试验地点
- 71
- 主要终点
- Response according to RECIST criteria
研究概览
简要总结
Phase II Study to evaluate the response on two blocks of topotecan and carboplatin
详细描述
Phase II study for patients with chemosensible soft tissue sarcoma stage IV in children and adolescents ; response according to RECIST criteria following two blocks of combination therapy consisting of Topotecan and carboplatin
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Soft tissue sarcoma chemosensible, stage IV
- •age < 21
- •measurable tumor lesions
排除标准
- •Lack of cooperation by the patient
- •no willingness of follow-up examinations
- •participation on another clinical trial at the same time
- •death due to the sickness within four weeks
结局指标
主要结局
Response according to RECIST criteria
次要结局
- Toxicity
- Overall-Survival
- Event-free-survival
研究者
研究点 (71)
Loading locations...
相似试验
已完成
2 期
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung CancerCarcinoma, Small CellNCT00305942SCRI Development Innovations, LLC61
已完成
1 期
Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian CancerOvarian CancerNCT00170625North Eastern German Society of Gynaecological Oncology28
已完成
2 期
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical CancerCervical CancerNCT00548418Washington University School of Medicine27
已完成
2 期
Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IVNon Small Cell Lung CancerNCT00614965Hellenic Oncology Research Group124
已完成
2 期
END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal DoxorubicinEndometrial CancerNCT00401635National Cancer Institute, Naples42